Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ingeborgh van den Born

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Retinal Cases & Brief Reports|November 13, 2014
Sclerochoroidal calcification: idiopathic or associated with systemic disease?Eric W Lindstedt, L Ingeborgh van den Born, Marc Veckeneer, et al.
The British Journal of Ophthalmology|October 26, 2010
The conclusions of Clemson et al concerning valproic acid are prematureMary J van Schooneveld, L Ingeborgh van den Born, Mies van Genderen, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|January 19, 2021
Reactivation of CNV after Discontinuation of Bevacizumab Treatment of Age-Related Macular DegenerationSankha Amarakoon, Jose P Martinez-Ciriano, Seerp Baarsma, et al.
Acta Ophthalmologica|October 29, 2018
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeksSankha Amarakoon, José P Martinez-Ciriano, L Ingeborgh van den Born, et al.
Ophthalmic Research|March 8, 2021
Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research NetworkBirgit Lorenz, Joana Tavares, L Ingeborgh van den Born, et al.
Ophthalmic Research|January 19, 2021
Current Management of Inherited Retinal Degeneration Patients in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research NetworkBirgit Lorenz, Joana Tavares, L Ingeborgh van den Born, et al.
Acta Ophthalmologica|June 19, 2013
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeksTanya Lushchyk, Sankha Amarakoon, José P Martinez-Ciriano, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 6, 2002
Hereditary X-linked juvenile retinoschisis: a review of the role of Müller cellsCornelia M Mooy, L Ingeborgh Van Den Born, Seerp Baarsma, et al.
European Journal of Ophthalmology|April 9, 2020
A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakageTom Oar Missotten, Johan G Hoddenbach, Christine Ae Eenhorst, et al.
Plos One|August 29, 2012
Expression of wild-type Rp1 protein in Rp1 knock-in mice rescues the retinal degeneration phenotypeQin Liu, Rob W J Collin, Frans P M Cremers, et al.
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Retinal Cases & Brief Reports|November 13, 2014
Sclerochoroidal calcification: idiopathic or associated with systemic disease?Eric W Lindstedt, L Ingeborgh van den Born, Marc Veckeneer, et al.
The British Journal of Ophthalmology|October 26, 2010
The conclusions of Clemson et al concerning valproic acid are prematureMary J van Schooneveld, L Ingeborgh van den Born, Mies van Genderen, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|January 19, 2021
Reactivation of CNV after Discontinuation of Bevacizumab Treatment of Age-Related Macular DegenerationSankha Amarakoon, Jose P Martinez-Ciriano, Seerp Baarsma, et al.
Acta Ophthalmologica|October 29, 2018
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeksSankha Amarakoon, José P Martinez-Ciriano, L Ingeborgh van den Born, et al.
Ophthalmic Research|March 8, 2021
Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research NetworkBirgit Lorenz, Joana Tavares, L Ingeborgh van den Born, et al.
Ophthalmic Research|January 19, 2021
Current Management of Inherited Retinal Degeneration Patients in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research NetworkBirgit Lorenz, Joana Tavares, L Ingeborgh van den Born, et al.
Acta Ophthalmologica|June 19, 2013
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeksTanya Lushchyk, Sankha Amarakoon, José P Martinez-Ciriano, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|July 6, 2002
Hereditary X-linked juvenile retinoschisis: a review of the role of Müller cellsCornelia M Mooy, L Ingeborgh Van Den Born, Seerp Baarsma, et al.
European Journal of Ophthalmology|April 9, 2020
A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakageTom Oar Missotten, Johan G Hoddenbach, Christine Ae Eenhorst, et al.
Plos One|August 29, 2012
Expression of wild-type Rp1 protein in Rp1 knock-in mice rescues the retinal degeneration phenotypeQin Liu, Rob W J Collin, Frans P M Cremers, et al.
Pageof 13